IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas

Autor: G. Sari, K. Dhatchinamoorthy, L. Orellano-Ariza, L. M. Ferreira, M. A. Brehm, K. Rock

Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-16 (2024)

Abstract Background In order for cancers to progress, they must evade elimination by CD8 T cells or other immune mechanisms. CD8 T cells recognize and kill tumor cells that display immunogenic tumor peptides bound to MHC I molecules. One of the ways

Externí odkaz: https://doaj.org/article/4da94f8b8b6c4089b6b46157d67f4054

IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas.

Autor: Sari G; Department of Pathology, UMass Chan Medical School, Worcester, MA, USA., Dhatchinamoorthy K; Department of Pathology, UMass Chan Medical School, Worcester, MA, USA., Orellano-Ariza L; Department of Pathology, UMass Chan Medical School, Worcester, MA, USA., Ferreira LM; Program in Molecular Medicine, Diabetes Center of Excellence, UMass Chan Medical School, Worcester, MA, USA., Brehm MA; Program in Molecular Medicine, Diabetes Center of Excellence, UMass Chan Medical School, Worcester, MA, USA Kenneth Rock., Rock K; Department of Pathology, UMass Chan Medical School, Worcester, MA, USA.

Publikováno v: Research square [Res Sq] 2024 Sep 02. Date of Electronic Publication: 2024 Sep 02.